{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T22:39:33Z","timestamp":1762987173807,"version":"3.45.0"},"reference-count":14,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,1,19]],"date-time":"2021-01-19T00:00:00Z","timestamp":1611014400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jtocrr.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JTO Clinical and Research Reports"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.jtocrr.2021.100149","type":"journal-article","created":{"date-parts":[[2021,2,2]],"date-time":"2021-02-02T12:52:07Z","timestamp":1612270327000},"page":"100149","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Current Landscape of Immunotherapy Trials Involving the Programmed Cell Death Protein 1\/Programmed Death-Ligand 1 Axis in Intrathoracic Tumors"],"prefix":"10.1016","volume":"2","author":[{"given":"Samuel A.","family":"Kareff","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suraj","family":"Samtani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mauricio","family":"Burotto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vinay","family":"Prasad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chul","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtocrr.2021.100149_bib1","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.2535","article-title":"Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs","volume":"2","author":"Haslam","year":"2019","journal-title":"JAMA Netw Open"},{"author":"Upadhaya","key":"10.1016\/j.jtocrr.2021.100149_bib2"},{"key":"10.1016\/j.jtocrr.2021.100149_bib3","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1038\/nrd.2018.167","article-title":"Trends in the global immuno-oncology landscape [published correction appears in Nat Rev Drug Discov. 2018;17:922]","volume":"17","author":"Tang","year":"2018","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jtocrr.2021.100149_bib4","doi-asserted-by":"crossref","first-page":"4950","DOI":"10.1158\/1078-0432.CCR-16-3079","article-title":"Challenges and opportunities in adapting clinical trial design for immunotherapies","volume":"23","author":"Siu","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtocrr.2021.100149_bib5","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1093\/annonc\/mdx755","article-title":"Comprehensive analysis of the clinical immuno-oncology landscape","volume":"29","author":"Tang","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtocrr.2021.100149_bib6","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0229206","article-title":"Assessing the binding properties of the anti-PD-1 antibody landscape using label-free biosensors","volume":"15","author":"Brown","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.jtocrr.2021.100149_bib7","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1053\/j.seminoncol.2017.06.002","article-title":"A\u00a0molecular and preclinical comparison of the PD-1-targeted T-cell checkpoint inhibitors nivolumab and pembrolizumab","volume":"44","author":"Fessas","year":"2017","journal-title":"Semin Oncol"},{"key":"10.1016\/j.jtocrr.2021.100149_bib8","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/nrclinonc.2017.31","article-title":"The high price of anticancer drugs: origins, implications, barriers, solutions","volume":"14","author":"Prasad","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jtocrr.2021.100149_bib9","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/S1470-2045(20)30329-6","article-title":"Clinical development of immuno-oncology in China","volume":"21","author":"Wu","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtocrr.2021.100149_bib10","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1001\/jamaoncol.2019.0167","article-title":"Analysis of control arm quality in randomized clinical trials leading to anticancer drug approval by the US Food and Drug Administration","volume":"5","author":"Hilal","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jtocrr.2021.100149_bib11","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1001\/jamainternmed.2020.2250","article-title":"Limitations in clinical trials leading to anticancer drug approvals by the US Food and Drug Administration","volume":"180","author":"Hilal","year":"2020","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jtocrr.2021.100149_bib12","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1056\/NEJMra1510062","article-title":"Master protocols to study multiple therapies, multiple diseases, or both","volume":"377","author":"Woodcock","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtocrr.2021.100149_bib13","article-title":"Master protocols in immuno-oncology: do novel drugs deserve novel designs?","volume":"8","author":"Mazzarella","year":"2020","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.jtocrr.2021.100149_bib14","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/PPO.0000000000000321","article-title":"The partnership for accelerating cancer therapies","volume":"24","author":"Baker","year":"2018","journal-title":"Cancer J"}],"container-title":["JTO Clinical and Research Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666364321000084?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666364321000084?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T22:35:46Z","timestamp":1762986946000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666364321000084"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":14,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["S2666364321000084"],"URL":"https:\/\/doi.org\/10.1016\/j.jtocrr.2021.100149","relation":{},"ISSN":["2666-3643"],"issn-type":[{"type":"print","value":"2666-3643"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current Landscape of Immunotherapy Trials Involving the Programmed Cell Death Protein 1\/Programmed Death-Ligand 1 Axis in Intrathoracic Tumors","name":"articletitle","label":"Article Title"},{"value":"JTO Clinical and Research Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtocrr.2021.100149","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc. on behalf of the International Association for the Study of Lung Cancer.","name":"copyright","label":"Copyright"}],"article-number":"100149"}}